Talis Biomedical Corporation (TLIS)

NASDAQ: TLIS · IEX Real-Time Price · USD

9.14

+0.25 (2.81%)

At close: Apr 26, 2024, 3:22 PM

9.00

-0.14 (-1.53%)

After-hours: Apr 26, 2024, 6:59 PM EDT

Talis Biomedical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	2.13	4.81	8.19	10.94	3.98	2.39
Revenue Growth (YoY)	-55.65%	-41.27%	-25.10%	175.03%	66.40%	-
Cost of Revenue	0.04	8.39	0	0	0	0
Gross Profit	2.09	-3.58	8.19	10.94	3.98	2.39
Selling, General & Admin	28.21	40.73	42.42	13.1	6.86	5.43
Research & Development	40.69	70.83	157.59	89.02	23.81	18.39
Operating Expenses	68.91	111.56	200.01	102.12	30.68	23.82
Operating Income	-66.82	-115.14	-191.82	-91.18	-26.7	-21.43
Other Expense / Income	-4.81	-2.13	0.22	-0.05	0.78	-0.09
Pretax Income	-62.01	-113.01	-192.04	-91.13	-27.47	-21.34
Net Income	-62.01	-113.01	-192.04	-91.13	-27.47	-21.34
Preferred Dividends	0	0	0	0	-53.86	0
Net Income Common	-62.01	-113.01	-192.04	-91.13	26.38	-21.34
Shares Outstanding (Basic)	2	2	2	0	0	0
Shares Outstanding (Diluted)	2	2	2	0	0	0
Shares Change	0.95%	19.21%	968.49%	-1.41%	309.46%	-
EPS (Basic)	-34.12	-62.77	-127.20	-644.70	515.10	-609.30
EPS (Diluted)	-34.12	-62.77	-127.20	-644.70	-191.55	-609.30
Free Cash Flow	-53.73	-101.75	-174.25	-95.23	-24.9	-21.48
Free Cash Flow Per Share	-29.56	-56.51	-115.37	-673.66	-486.17	-613.32
Gross Margin	98.08%	-74.38%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-3130.97%	-2392.75%	-2341.22%	-833.64%	-671.34%	-896.65%
Profit Margin	-2905.67%	-2348.55%	-2343.90%	-833.15%	663.36%	-892.76%
Free Cash Flow Margin	-2517.62%	-2114.53%	-2126.82%	-870.59%	-626.20%	-898.58%
EBITDA	-56.93	-101.41	-189.42	-89.76	-26.75	-20.69
EBITDA Margin	-2667.90%	-2107.46%	-2311.91%	-820.59%	-672.57%	-865.69%
Depreciation & Amortization	5.07	11.6	2.62	1.37	0.73	0.65
EBIT	-62.01	-113.01	-192.04	-91.13	-27.47	-21.34
EBIT Margin	-2905.67%	-2348.55%	-2343.90%	-833.15%	-690.82%	-892.76%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).